|
|
Article: Barr Announces Agreements with Cephalon, Inc. Regarding Settlement of ACTIQ(R) and PROVIGIL(R) Patent Litigations.
- Article from:
- PR Newswire
- Article date:
- February 2, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
WOODCLIFF LAKE, N.J., Feb. 1 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. today announced that its subsidiary, Barr Laboratories, Inc., and Cephalon, Inc. have entered into agreements to settle its pending patent infringement disputes in the United States related to Cephalon's ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II] and PROVIGIL(R) (modafinil) Tablets [C-IV] products.
"We are pleased that these agreements allow both parties to resolve pending patent litigation in a way that ensures that Barr can launch generic fentanyl at least 90 days prior to the expiration of any pediatric exclusivity period Cephalon might obtain on ACTIQ and can launch ...